免疫学
T细胞
CD19
乙型肝炎表面抗原
细胞因子
免疫系统
医学
CD40
外周血单个核细胞
B细胞
埃利斯波特
生物
细胞毒性T细胞
体外
乙型肝炎病毒
抗体
病毒
生物化学
作者
Natarajan Ayithan,Lydia Tang,Susanna K. Tan,Diana Chen,Jeffrey J. Wallin,Simon P. Fletcher,Shyam Kottilil,Bhawna Poonia
标识
DOI:10.3389/fimmu.2021.735913
摘要
Identifying signaling pathways that induce B cell response can aid functional cure strategies for chronic hepatitis B infection (CHB). TLR8 activation with ssRNA was shown to enhance follicular helper T cell (T FH ) function leading to improved B cell responses in vitro . We investigated whether this mechanism can rescue an exhausted immune response in CHB infection. Effect of TLR8 agonism on supporting cytokines and T FH and B cells were evaluated using ex vivo and in vitro assays. The ability of an oral TLR8 agonist to promote T FH and B cell response was tested in samples from phase 1b clinical trial. TLR8 agonism induced T FH polarizing cytokine IL-12 in monocytes. Treatment of peripheral blood mononuclear cells (PBMCs) from CHB patients with TLR8 agonists induced cytokine IL-21 by T FH cells with enhanced IL-21 + BCL-6 + and ICOS + BCL-6 + co-expression. Mechanistically, incubation of isolated naïve CD4 + T cells with TLR8 triggered monocytes resulted in their differentiation into IL-21 + ICOS + BCL-6 + T FH in an IL-12 dependent manner. Furthermore, co-culture of these IL-21 producing T FH with autologous naïve B cells led to enhanced memory (CD19 + CD27 + ) and plasma B cell generation (CD19 + CD27 ++ CD38 + ) and IgG production. Importantly, in T FH from CHB patients treated with an oral TLR8 agonist, HBsAg-specific BCL-6, ICOS, IL-21 and CD40L expression and rescue of defective activation induced marker (AIM) response along with partial restoration of HBsAg-specific B cell ELISPOT response was evident. TLR8 agonism can thus enhance HBV-specific B cell responses in CHB patients by improving monocyte-mediated T FH function and may play a role in achieving HBV functional cure.
科研通智能强力驱动
Strongly Powered by AbleSci AI